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Background: Malaria caused by Plasmodium vivax was long considered to have a low mortality, but recent reports
from some geographical areas suggest that severe and complicated vivax malaria may be more common than
previously thought.
Methods: The primary objective of this systematic review and meta-analysis was to describe the reported clinical
characteristics and the geographical variation in prevalence of reported severe vivax malaria and its change over
time derived from English-language articles published since 1900. Medline and Scopus databases were searched for
original papers on severe vivax malaria, using as inclusion criteria modified 2010 WHO criteria for the diagnosis of
severe falciparum malaria. Articles before 1949 were identified through reference lists in journals, textbooks, and
personal collections of colleagues.
Results: A total of 77 studies with reported severe vivax malaria and 63 studies with no reported severe vivax
malaria (totaling 46,411 and 6,753 vivax malaria patients, respectively) were included. The 77 studies with reported
severe vivax malaria were mainly from India (n = 33), USA (n = 8), Indonesia (n = 6), and Pakistan (n = 6). Vivax
endemic countries not reporting severe vivax malaria beyond individual case reports included: the Greater Mekong
Sub-region, China, North Korea, Bangladesh, Afghanistan, Middle East (except Qatar), the horn of Africa, and
Madagascar. Only 17/77 reports were from before 2000. Vivax mono-infection was confirmed by PCR in 14 studies
and co-morbidities were ruled out in 23 studies. Among the 77 studies reporting severe vivax malaria, severe
thrombocytopenia (<50,000/mm3) was the most common “severe” manifestation (888/45,775 with pooled prevalence
of 8.6%). The case fatality was 0.3% (353/46,411). Severity syndromes varied widely between different geographical
areas, with severe anaemia being most prominent in areas of high transmission and chloroquine resistance.
Conclusion: Plasmodium vivax can cause severe and even fatal disease, but there is a recent increase in reports over
the past 15 years with larger series restricted to a limited number of geographical areas. The biological basis of these
variations is currently not known. More detailed epidemiological studies are needed which dissociate causation from
association to refine the definition and estimate the prevalence of severe vivax malaria.
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Of the five Plasmodium species causing disease in
humans, Plasmodium falciparum is the main cause of
severe and fatal disease. Traditionally Plasmodium vivax
has been considered relatively benign, except for occasional
severe manifestations notably severe anaemia and the acute
respiratory distress syndrome [1]. Although death in P.
vivax infections has been recognized for over a century,
the last decade has seen a remarkable increase in case
reports, series and studies describing severe and fatal vivax
malaria. An estimated 2.8 billion people globally live in one
of the 95 countries endemic for P. vivax [2-5]. In general,
in P. vivax endemic areas transmission is low and seasonal
(Central, West, South, and South-East Asia), the Americas,
and the horn of Africa (and Madagascar); whereas the rest
of Africa is relatively spared because of the absence of the
Duffy blood group which mediates parasite invasion [5]. In
contrast transmission is substantially higher on the island
of New Guinea. India contributes nearly half (46%) , China
19%, while Indonesia and Pakistan together contribute 12%
of the global population at risk [5]. India has the majority
of clinical cases.
Occasional fatalities in vivax malaria have been re-
ported since the species was first recognized, particularly
in already debilitated patients, and significant mortality
has been attributed to vivax malaria in the first and sec-
ond world wars although details of speciation are often
scanty. Plasmodium vivax was associated with a 7.7%
mortality in the malariatherapy of neurosyphilis, but this
was attributed in part to the debilitated condition of the
patients and mortality in Plasmodium malariae infections
was even higher [6]. Early publications reporting severe
vivax malaria include case reports [7-9] and small case
series [10,11], but in recent years, larger studies conducted
in India, Indonesian Papua, and Papua New Guinea sug-
gest a stronger association between P. vivax infection, se-
vere disease and death than recognized previously
[12-16]. A systematic review and meta-analysis was con-
ducted from all identifiable English-language articles
published since 1900 reporting human cases of severe
P. vivax infection. The primary objective was to describe
the geographical variation in prevalence of severe vivax
malaria and the different presenting syndromes and
characteristics, as well as to analyse the changes in
reporting over time.
Methods
Search engines, terms, and strategies
Eligible studies on severe vivax malaria since 1949
were identified in Medline (via PubMed) and Scopus
(via Scopus). The final search and updates in both
databases were carried out on January 28, 2014. Articles
before 1949 (Pre-PubMed era) were mainly searched
through other sources including reference lists of publishedjournal articles and (old) textbooks and through gifts of
personal collections of colleagues. Details on variables,
search terms, and search strategies are explained in
Additional file 1.
Inclusion/exclusion criteria
All literature in English describing clinical studies in
human vivax malaria was considered, recognizing that
there is also a substantial literature in other languages.
Malaria was diagnosed by peripheral blood smear (PBS)
and in recent years by rapid diagnostic test (RDT) or
polymerase chain reaction (PCR). Since severity criteria
for severe vivax malaria have not been specified yet,
modified criteria defined in the 2010 WHO supplement
on severe falciparum malaria were used as the out-
come of interest used for inclusion, with the addition
of thrombocytopenia as this has been used as a severity
criterion in several publications (<50,000/mm3) [17]
[see Additional file 2]. It should be noted that throm-
bocytopenia is not a severity criterion for falciparum
malaria, and has never been validated as an independent
severity measure in vivax malaria. Only articles reporting
P. vivax mono-infection were selected. Studies included
those where the denominators were both inpatients and
outpatients with vivax malaria and studies reporting only
inpatients with vivax malaria patients. Exclusion criteria
included duplicate reporting, mixed infections (P. vivax
with any other Plasmodium species), and insufficient data
for extraction. All types of study designs with primary
data (having patients of either gender or any age)
were eligible, but case reports and case series were
not included in pooled calculations of prevalence because
the denominator was uncertain. The complete selected
articles were analysed and data were coded into a data
extraction form (DEF).
Bias assessment and quality assurance
Eligibility for inclusion of every article was reviewed
by independent reviewers (Bilal Ahmad Rahimi, Wali
Mohammad Wyar, and Arjen M. Dondorp). Disagreements
between reviewers were resolved by discussion, and
extracted data were validated by an independent person
(Watcharee Chokejindachai).
Statistical analysis





where p = Pooled prevalence of the severity signs among
vivax malaria patients;
pi = Prevalence of the severity sign in each study;
wi =1/var (pi), which was the weight of each study.
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was calculated only if it was reported in at least three
reports using the following command in STATA
pmeta n freq
where n = Total number of patients with a specific
severity sign due to vivax malaria; freq = Total number
of patients with vivax malaria in the study.
A subgroup analysis was performed in order to compare
prevalence of severity signs before and after 2000 and
between different WHO regions (Africa [AFRO], Americas
[AMRO], Eastern-Mediterranean [EMRO], Europe [EURO],
South-East Asia [SEARO], and Western Pacific [WPRO])
and countries, using Chi2 test. Software STATA version 12
(Stata Corp LP, Texas USA) was used for statistical analysis.
Results
Initially 274 and 412 studies were identified in the Medline
and Scopus databases, respectively. Of these, 289 were
duplicates and 278 were ineligible for other reasons,
including: only case reports and case series (n = 71),
non-English language (n = 41), and disease caused by
obvious co-morbidities (n = 8) (Figure 1). Twenty-oneFigure 1 Flow of study selection.additional studies (including studies from before 1949) were
included through search of reference lists or from reference
files provided by colleagues, providing a total of 77 studies
with severe vivax malaria patients and 63 studies with no
severe vivax malaria patients, comprising a total of 46,411
and 6,753 vivax malaria patients, respectively.
Characteristics of studies reporting severe vivax malaria
Characteristics of the 77 studies with severe vivax malaria
patients are explained in Additional file 3. Among them, 36
were retrospective hospital-based studies (RHBS) and 41
were prospective hospital-based studies (PHBS). Regarding
their geographical origin, 42 (54.5%), 17 (22.1%), 10 (13%),
and 8 (10.4%) were from SEARO, AMRO, EMRO, and
WPRO, respectively. Specified by country, 33 (42.9%), 8
(10.39%), 6 (7.8%), and 6 (7.8%) studies were reported from
India, USA, Pakistan, and Indonesia, respectively.
Pooled prevalence of severity signs from 140 studies
reporting on both severe and uncomplicated vivax
malaria
Overall 77 studies reported patients with severe vivax
malaria patients while 63 studies did not report any
patients as having severe vivax malaria.
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in studies with and without reported severe vivax
malaria patients are shown in Table 1 and Figure 2.
Among these studies, the pooled prevalence of the
five most commonly reported severity signs were:
severe thrombocytopenia 4.7% (95% CI: 2.3–7%),
severe anaemia 2% (95% CI: 1.3–2.8%), hepatic dys-
function 2% (95% CI: 1.3–2.7%), metabolic acidosis
0.5% (95% CI: 0–1.2%), and renal dysfunction 0.5%
(95% CI: 0–1%). Pooled mortality was 0.1% (95% CI:
0–0.2%).
Pooled prevalence of severity signs from 77 studies
reporting on severe vivax malaria only
Among 77 studies with reported severe vivax malaria
patients, 43 reported hepatic dysfunction, 42 cerebral
malaria, 37 deaths, 34 severe anaemia, 27 severe
thrombocytopenia, 27 respiratory dysfunction, 24
abnormal bleeding/DIC, 20 renal dysfunction, 14
hypoglycaemia, 11 generalized seizures, 11 circulatory
collapse/shock, 10 haemoglobinuria, and eight studies
reported metabolic acidosis. The pooled prevalence of
the various severity signs in studies with reported se-
vere vivax malaria patients are shown in Table 2 and
Figure 3. Among these studies, the pooled prevalence
of the five most commonly reported severity signs
were: severe thrombocytopenia 8.6% (95% CI: 5.4–11.8%),
shock 5.1% (95% CI: 2.5–7.7%), hepatic dysfunction 4.2%
(95% CI: 3.2–5.2%), severe anaemia 4% (95% CI: 2.9–5.1%),
and hypoglycaemia 1.8% (95% CI: 0.9–2.7%). Pooled
mortality was 0.3% (95% CI: 0.1–0.4%). Detailed ana-
lysis of pooled prevalence of severity signs among
reported severe vivax malaria patients are shown in
Additional file 4.Table 1 Pooled prevalence of the various severity signs in stu
patients (140 studies)
Complication Total vivax Total patients w
Death 53164 353
Cerebral malaria 52598 532
Multiple convulsions 53139 88
Renal dysfunction 53094 244
Respiratory dysfunction 53164 144
Hepatic dysfunction 53289 727
Abnormal bleeding/DIC 53099 206
Haemoglobinuria 53164 93
Hypoglycaemia 53134 44
Metabolic acidosis 53094 138
Circulatory collapse/Shock 53164 67
Severe anaemia 53164 2276
Severe thrombocytopenia 52528 888Comparisons with falciparum malaria
In Indonesian Papua, coma associated with PCR-confirmed
P. vivax mono-infection (and without overt co-morbidities)
occurred 23 times less frequently than that seen with
falciparum malaria and was estimated as occurring in
one in 29,500 infections [18]. In Thailand, the risk
of hospitalization with impaired consciousness with
microscopy-diagnosed P. vivax (not PCR-confirmed)
was one in 858 infections, with the risk being 15.2
fold less than that with P. falciparum [19]. Mortality
was 0.22% in children hospitalized in Eastern Thailand
with vivax malaria (concomitant falciparum malaria
excluded by microscopy only) [20].
Pooled prevalence of severity signs in vivax malaria from
62 studies reporting on both inpatients and outpatients
Among 77 studies with severe vivax malaria patients,
62 studies reported severity signs in both inpatients
and outpatients of vivax malaria. In these studies, 31
reported cerebral malaria, six generalized seizures, 14
renal dysfunction, 19 respiratory dysfunction, 31 hepatic
dysfunction, 17 abnormal bleeding/DIC, seven haemo-
globinuria, eight hypoglycaemia, four metabolic acidosis,
six circulatory collapse/shock, 23 severe anaemia, 21
severe thrombocytopenia, and 28 studies reported
fatal cases [see Additional files 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16 and 17].
The pooled prevalence of the various severity signs
in studies that reported both inpatients and outpa-
tients of vivax malaria are shown in Additional file 18
and Figure 4. The pooled prevalence of the five most
commonly reported severity signs were: severe
thrombocytopenia 7.5% (95% CI: 4.2–10.8%), shock
3.3% (95% CI: 1.1–5.4%), severe anaemia 2.8% (95% CI:dies with and without reported severe vivax malaria














Figure 2 Forest plot of pooled prevalences of the severity signs in P. vivax malaria patients in studies with and without reported
severe vivax malaria patients (140 studies).
Rahimi et al. Malaria Journal 2014, 13:481 Page 5 of 10
http://www.malariajournal.com/content/13/1/4811.8–3.9), hepatic dysfunction 2.5% (95% CI: 1.7–3.4%), and
hypoglycaemia 2% (95% CI: 0.8–3.2%). Pooled mortal-
ity was 0.2% (95% CI: 0.1–0.3%).
Pooled prevalence of severity signs in vivax malaria from
15 studies reporting on inpatients only
Among 77 studies with severe vivax malaria patients, 15
studies described severity signs only in inpatients vivax
malaria. In these studies, 11 reported cerebral malaria, 5
repeated generalized seizures, 6 renal dysfunction, 8
respiratory dysfunction, 12 hepatic dysfunction, 7 abnormal
bleeding/DIC, 3 haemoglobinuria, 6 hypoglycaemia, 4
metabolic acidosis, 5 circulatory collapse/shock, 10
severe anaemia, 6 severe thrombocytopenia, and 9 studies
reported deaths [see Additional files 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, 30 and 31].
The pooled prevalence of severity signs among re-
ported inpatients with vivax malaria are shown in
Additional file 32 and Figure 5. The five most common
severity manifestations were death 28.2% (95% CI:Table 2 Pooled prevalence of severity signs among reported
Complication Total vivax Total patients w
Death 46411 353
Cerebral malaria 45845 532
Multiple convulsions 46386 88
Renal dysfunction 46341 244
Respiratory dysfunction 46411 144
Hepatic dysfunction 46536 727
Abnormal bleeding/DIC 46346 206
Haemoglobinuria 46411 93
Hypoglycaemia 46381 44
Metabolic acidosis 46341 138
Circulatory collapse/Shock 46411 67
Severe anaemia 46411 2276
Severe thrombocytopenia 45775 88826.6–29.7%), hepatic dysfunction 19.5% (95% CI: 12.6–
26.3%), severe anaemia 17.3% (95% CI: 9.1–25.4%), and se-
vere thrombocytopenia 13.9% (95% CI: 0–29.1%).
Comparison of severity signs between vivax and
falciparum malaria
Figure 6 shows the Pf:Pv ratio for all signs of malaria
severity. Highest mean Pf:Pv ratio was present for fatal-
ities (4.0), followed by repeated generalized seizures
(3.64), renal dysfunction (2.85), hypoglycaemia (2.75),
and cerebral malaria (2.73). Lowest mean Pf:Pv ratio
was for severe thrombocytopenia (1.19) and respira-
tory dysfunction (1.37).
Discussion
There is substantial variation in the reported geographic
distribution and the incidence of severe manifestations of
vivax malaria. This analysis also shows a large increase
since the year 2000 in the number of studies and numbers
of patients reported with severe P. vivax infections, (whichsevere vivax malaria patients (77 studies)














Figure 3 Forest plot of pooled prevalences of the severity signs in P. vivax malaria patients in studies with reported severe vivax
malaria patients (77 studies).
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PCR). Of these 33 (42.9%) studies came from India.
In contrast, a large number of endemic countries do
not report severe vivax malaria, including the Greater
Mekong Sub-region, North-east China, North-Korea,
Bangladesh, Afghanistan, Middle East (except Qatar),
Somalia, and Madagascar. There are two general presenta-
tions reported; severe anaemia in young children from the
island of New Guinea where transmission is high, and vital
organ dysfunction usually in adults from low transmission
settings. A large variation in organ involvement was
observed in the latter group. Vivax malaria was reported
as an important cause of hospital admission in endemic
areas, but a major problem in determining the true inci-
dence and prevalence of severe vivax malaria is that severe
disease has been considered relatively unusual in vivax
malaria, and so its absence from a clinical series has not
been considered noteworthy. For example in over 1,000
patients with severe malaria admitted to a centre in Ho
Chi Minh city, Vietnam, specializing in its management
there was one case of severe vivax (cerebral) malaria and
no cases of vivax malaria associated acute renal failure
(TT Hien & NP Phu: personal communication), but this
paucity of severe disease was not considered noteworthyFigure 4 Forest plot of pooled prevalences of the severity signs in P.
and outpatients of P. vivax malaria (62 studies).and so not reported. This contrasts with a prevalence of
severe disease amongst admitted cases of over 30% in
some series. Thus estimating incidence and prevalence
from series which do report severe vivax malaria provides
overestimates. Furthermore the most prevalent severity
sign reported was thrombocytopenia <50,000/μL (26.1%),
which is not regarded as a severity sign in falciparum mal-
aria, and has not been validated as an independent severity
measure in vivax malaria. The least prevalent manifest-
ation was haemoglobinuria (0.1%). In studies with only
inpatients of vivax malaria, thrombocytopenia (35.9%) was
the most commonly reported severity sign, while least
prevalent severity sign was respiratory dysfunction (1%).
Mortality in studies with only inpatients of vivax malaria
was 28.2%, compared to 0.2% in groups with both inpa-
tients and outpatients of vivax malaria.
How can the sharp increase in reported cases of severe
vivax malaria, the geographical heterogeneity, and the
different severe manifestations be explained?
It seems unlikely that underreporting can explain the scar-
city of cases in the last century, although there are only few
data to support this. A study in American and Allied sol-
diers in India reported in 1944, described cerebral malariavivax malaria patients in studies that reported both inpatients
Figure 5 Forest plot of pooled prevalence of the severity signs in P. vivax malaria patients in studies that reported only inpatients of
P. vivax malaria (15 studies).
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(3.5%) with P. falciparum or mixed infection [21]. An In-
dian study from 1982 reported severe malaria in 4/178
(2.2%) patients with P. vivax compared to 64/382 (17%)
with P. falciparum or mixed infection [22]. A more recent
Indian study showed a substantially higher proportion of
patients (50/338 (15%)) having severe vivax malaria [16].
One contributor to this discrepancy is the inclusion of
thrombocytopenia as a severity criterion in recent series.
The geographical heterogeneity is more substantiated
by data; a study from the Thai-Myanmar border from
1997 describes a very low incidence of patients with
severe P. vivax malaria (3 out of 2573 patients) [19].
A case of P. vivax-related pulmonary oedema has
been reported from this area [23].
Can the increase in chloroquine resistance account for
the observed geographical differences?
Chloroquine resistance has been well documented on
the Island of New Guinea (Papua New Guinea [24] andFigure 6 Pf:Pv ratio of severity signs in P. vivax and P. falciparum malIndonesian Papua [25,26] and more recently in Amazonas
[27]. All these regions report severe vivax malaria. On the
other hand, chloroquine resistance has not been clearly
described in other areas also reporting severe cases,
including India [28-31] and Pakistan [32,33], although
study methodology was not optimal. Chloroquine resist-
ance in settings where chloroquine is still widely used will
extend the duration of illness considerably, and recurrent
infection is expected to result in an increase in patients
presenting with severe anaemia. Indeed, severe anaemia is
by far the most common presentation in PNG and
Indonesia (a high transmission setting where children
are affected predominantly), but less so in Amazonia
(a low transmission setting where adults are affected
predominantly). Compounding factors to severe anaemia
include falciparum malaria, intestinal helminths and nutri-
tional deficiencies [34,35]. A retrospective study in Indones-
ian Papua reported similar adjusted odd ratios of death
associated with severe anaemia (Hb <5 g/dl) of 4.43 and
5.93 for P. vivax and P. falciparum, respectively. In thearia patients.
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malaria and thrombocytopenia <50,000/mm3 had an in-
creased mortality, although as not all the other clinical and
laboratory measures used to assess disease severity were re-
corded it is unclear whether thrombocytopenia was an in-
dependent risk factor or not [36]. In a study by Limaye and
colleagues in Mumbai, India, the most common severe
manifestation causing death was ARDS (six out of six
patients) [16].
Can the heterogeneity be explained by differences in
background P. vivax parasitaemia, resulting in
misdiagnosis of severe febrile illnesses with coincidental
P. vivax parasitaemia, analogous to the overdiagnosis of
falciparum malaria as a cause of illness in parasitaemic
African children?
There are few data available, but in Bikaner (India)
where many of the Indian reports on severe malaria
originate, the population prevalence of vivax malaria
is only around 1% (Maude RE, personal communication).
In contrast, the population prevalence is higher in
endemic regions Myanmar [37,38], which does not
report severe vivax. In this review, 23/77 (29.9%)
studies attempted to rule out possible co-morbidities
as confounders. One possibility is that other severe
febrile illnesses could reactivate hepatic hypnozoites
resulting in relapse. High vivax relapse rates, up to
over 40%, have been observed following P. falciparum
infection [39-41]. Of the reported studies, only 11
(18.6%) studies used PCR for confirmation of P.
vivax mono-infection, but even this would not rule
out recently cleared falciparum infection. Typhoid
fever, relapsing fever, trench fever, epidemic typhus,
and brucellosis have been incriminated as activating
P. vivax hypnozoites [42]. In many of the published
studies there were only limited efforts to rule out
other diseases, including falciparum malaria, bacterial
diseases, and viral diseases [13,43,44]. Regions could also
vary in prevalence of other severe chronic illnesses [45].
Further detailed study of the reported severe manifesta-
tions might shed some light on pathogenesis. In Bikaner,
where severe vivax malaria is commonly reported, high
rates of acute kidney injury are reported in severe vivax
malaria in children aged 0–5 years (8/41: 19.5%), an age
group in whom acute tubular necrosis (the pathology impli-
cated in falciparum malaria associated renal failure) is rare.
Acidosis was reported in 7/65 children with vivax mal-
aria (mean arterial pH 7.1) but its aetiology was un-
clear. In falciparum malaria acidosis is associated with
a high lactate-pyruvate ratio indicating an anoxic
pathogenesis, whereas in sepsis lactic pyruvate rations
are not elevated. There is clearly a need for more in-depth
prospective epidemiological studies, where background
age-stratified population P. vivax parasitaemia prevalenceis documented and there is proper evaluation of other
concomitant illnesses. One such study from Papua,
Indonesia, comparing population prevalence with coma in
hospitalized patients estimated the incidence of cerebral
malaria as 1:29,486 in P. vivax compared to 1:1,276
in P. falciparum infections. This suggested that P.
vivax-associated coma is 23 times less common than
P. falciparum-associated coma [18].
Are P. vivax strains associated with severe disease
intrinsically more pathogenic?
Epidemics of severe vivax malaria were reported from the
USSR over fifty years ago. Changes in strain virulence
could explain the recent and geographical restricted
increase in reported cases, although there are no hard data
available to support this hypothesis. Vivax strains clearly
do differ between regions, which is most evident in the
observed relapse patterns. Pathophysiological studies
exploring difference in parasite virulence could reveal
whether more virulent strains of this parasite with a once
benign reputation have appeared.
An earlier systematic review on complicated vivax
malaria in South America was reported by Lacerda and
colleagues in 2012 [46]. In this review, most of the informa-
tion derived from non-peer reviewed sources (including
masters’ dissertations, doctoral theses, and national
congresses’ abstracts) and all data came from the Brazilian
literature [46]. A recent review by Baird included all
published literature on all types of studies, including case
reports (since 1990) and case series [47].
This analysis had several limitations. The pooled
prevalence estimates of severe manifestations are based
only on reported studies which include cases of severe
vivax malaria and this provides a selection bias. Absence
of severe disease amongst patients with vivax malaria
appears much less likely to be reported. Assessing
the pooled prevalence of severe vivax malaria against
the general population or all vivax malaria cases as
denominator is not feasible with the current data.
Nearly all the estimated worldwide 390 million clinical
cases of vivax malaria/year [4] are not reported in the
studies. Except for one community-based study [14],
all of the studies included in this systematic review are
hospital-based, excluding case reports or small case series.
As a consequence, the estimated pooled prevalence of the
different severity manifestations represents proportions
amongst patients considered sufficiently ill to warrant
hospital admission. In addition, no definite criteria for
the diagnosis of severe vivax malaria currently exist
(they are “borrowed” from falciparum malaria except
for the addition of thrombocytopenia, which has been
inadequately justified), and many of the studies did
not exclude possible co-morbidities or possible mixed
Plasmodium infection. Another shortcoming is that we
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significant literature in other languages, e.g. reports from
Amazonia are often in Portuguese.
In summary, there has been a marked increase in re-
ported cases of severe vivax in certain geographical re-
gions of the P. vivax endemic world, which cannot be
explained with the current understanding of the disease
and warrants further study into its aetiology. The use of
thrombocytopenia as an independent severity criterion
requires justification. In addition, more detailed epidemio-
logical studies are needed, which adequately exclude co-
morbidities, and take into account transmission intensity
and anti-malarial drug susceptibility. As for severe P. fal-
ciparum malaria, P. vivax-specific criteria for defining
severe disease are necessary to facilitate comparison
between studies and establish its true prevalence.Additional files
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